Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Must have received: anti-PD-L1 therapy in combination with anti-VEGF therapy (atezolizumab, bevacizumab) — first line systemic therapy for advanced disease

Previously progressed on atezolizumab in combination with bevacizumab as first line systemic therapy for advanced disease

Cannot have received: multi-kinase inhibitor (cabozantinib, lenvatinib, sorafenib, regorafenib)

Exception: Use for adjuvant or loco-regional therapies allowed if completed ≥ 6 months prior to randomization

Prior multi-kinase inhibitor treatment for advanced disease (e.g., cabozantinib, lenvatinib, sorafenib, regorafenib)

Cannot have received: major surgery

Major surgery ≤ 4 weeks prior to randomization

Cannot have received: minor surgery

Minor surgery ≤ 7 days prior to randomization

Cannot have received: anti-cancer agent

Any anti-cancer agent ≤ 2 weeks prior to randomization

Cannot have received: radiation therapy

Exception: 1 week for palliative radiation for bone metastases and/or for pain control

Radiation therapy ≤ 4 weeks (1 week for palliative radiation for bone metastases and/or for pain control)

Cannot have received: radionuclide treatment (I-131, Y-90)

radionuclide treatment (e.g., I-131 or Y-90) ≤ 6 weeks prior to randomization

Cannot have received: investigational therapy

Treatment with investigational therapy ≤ 28 days prior to randomization

Cannot have received: CD137 agonist

Prior treatment with CD137 agonists

Cannot have received: immune checkpoint blockade therapies (anti-CTLA-4, anti-PD-1, anti-PD-L1)

Exception: Prior treatment with atezolizumab is permitted

Prior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies